Chai Discovery Signs GSK Deal to Design Biologics with AI

· Health · United States · United Kingdom

Chai Discovery has signed a deal with GSK to make biologics using AI, Endpoints News reported. The agreement follows the startup's earlier collaboration with Eli Lilly, which chief executive Joshua Meier pitched at the start of 2026 as just the beginning. Meier has described a "year of deployment" for the company's AI drug-design capabilities. The deal adds to a growing wave of partnerships between large pharmaceutical companies and AI-focused biotech startups aimed at accelerating discovery of biologic medicines.

Why it matters：AI-driven biologics design is becoming a core battleground in drug discovery, and pharma's willingness to sign repeat deals with young AI firms shows how quickly computational methods are being folded into pipelines.

Key points

  • The deal covers using AI to make biologics.
  • Chai Discovery previously collaborated with Eli Lilly.
  • CEO Joshua Meier called 2026 a "year of deployment."

Sources (original reporting)

More stories from this day